TELA Bio CEO buys 15,000 shares in August trade

TELA Bio, Inc. director and Chief Executive Officer Heather C. Getz purchased 15,000 shares of common stock on 2026-08-14 in an open-market or private transaction.

Rhea-AI Filing Summary

TELA Bio, Inc. director and Chief Executive Officer Heather C. Getz purchased 15,000 shares of common stock on 2026-08-14 in an open-market or private transaction. The weighted average purchase price was about $0.6978 per share, with individual trades between $0.697 and $0.6994. Following this transaction, she directly holds 520,000 shares of TELA Bio common stock.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Getz Heather C

Role Chief Executive Officer

Bought 15,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	15,000	$0.6978	$10K

Holdings After Transaction: Common Stock — 520,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.697 to $0.6994. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 15,000 shares Weighted average purchase price: $0.6978 per share Purchase price range: $0.697 to $0.6994 per share +1 more

4 metrics

Shares purchased 15,000 shares Common Stock purchased by Heather C. Getz on 2026-08-14

Weighted average purchase price $0.6978 per share Average price paid for 15,000-share purchase on 2026-08-14

Purchase price range $0.697 to $0.6994 per share Range of prices for multiple trades comprising the 15,000-share purchase

Shares owned after transaction 520,000 shares Direct TELA Bio common stock holdings of Heather C. Getz following the purchase

Key Terms

weighted average price, open market or private transaction, Common Stock

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction code description Purchase in open market or private transaction"

Common Stock financial

"security_title Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TELA (TELA Bio, Inc.) report for Heather C. Getz?

Heather C. Getz, TELA Bio’s Chief Executive Officer and director, reported buying 15,000 shares of the company’s common stock on 2026-08-14. The transaction was reported as a purchase in an open market or private transaction.

At what price did Heather C. Getz buy TELA (TELA Bio, Inc.) shares?

Heather C. Getz bought the 15,000 TELA shares at a weighted average price of $0.6978 per share. According to the disclosure, individual trades occurred in a price range from $0.697 to $0.6994 per share.

How many TELA (TELA Bio, Inc.) shares does Heather C. Getz own after this transaction?

After the reported purchase, Heather C. Getz directly owns 520,000 shares of TELA Bio common stock. This figure reflects her direct holdings following the 15,000-share acquisition disclosed in the Form 4.

Was Heather C. Getz’s TELA (TELA Bio, Inc.) share purchase made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not marked as a plan trade. There is no footnote stating that the 15,000-share purchase was executed under a pre-arranged Rule 10b5-1 trading plan.

What does the weighted average price mean in Heather C. Getz’s TELA (TELA Bio, Inc.) trade?

The reported $0.6978 weighted average price means the 15,000 shares were bought in multiple trades between $0.697 and $0.6994. The company notes that detailed price-by-trade information is available upon request from specified parties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/17/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Getz Heather C

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		P		15,000	A	$0.6978(1)	520,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.697 to $0.6994. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Megan Smeykal, Attorney-in-Fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)